SEC Filing Summary: SIGA Technologies, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by SIGA Technologies, Inc. on March 13, 2013, reporting events occurring on March 12, 2013. The company is a Delaware corporation focused on developing antiviral drugs, specifically reporting on the delivery of its proprietary smallpox antiviral drug, Arestvyr.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on a specific operational milestone rather than periodic financial results.
Material Changes
The primary material event reported is the delivery of approximately 190,000 courses of Arestvyr to the United States Government's Strategic National Stockpile. This transaction represents the first delivery under a contract with the Biomedical Advanced Research and Development Authority (BARDA).
Guidance, Outlook, and Risks
Management commentary indicates that this delivery is the first of a series of deliveries pursuant to the existing contract with BARDA. The filing does not contain updated financial guidance, specific risk factors, or details on contingencies beyond the execution of the contract terms.
Key Facts for Investor Verification
- Confirmation of the total contract value and payment terms associated with the BARDA agreement.
- Details regarding the schedule and volume of subsequent Arestvyr deliveries.
- Impact of this delivery on the company's cash position and future revenue recognition.
- Regulatory status and approval timeline for Arestvyr beyond the current stockpile contract.